Methods for iontophoretically treating nausea and migraine

Patent metadata

Field	Value
Publication number	US-9592291-B2
Application number	US-201414497595-A
Country	US
Kind code	B2
Filing date	Sep 26, 2014
Priority date	Aug 10, 2009
Publication date	Mar 14, 2017
Grant date	Mar 14, 2017

Abstract

Methods for treating nausea and migraine by iontophoretically administering triptan compounds are provided.

First claim

We claim:

1. A method for treating photophobia or phonophobia in a subject suffering from a migraine, the method comprising: iontophoretically administering an effective amount of a triptan compound to a subject suffering from a migraine, such that the photophobia or phonophobia is treated without cardiovascular side effects, wherein the triptan compound is administered iontophoretically in a two phase manner, comprising:
a first phase, wherein the triptan compound is administered with a current of about 4 mA for about an hour; and
a second phase, wherein the triptan compound is administered with a current of about 2 mA for about three hours.

2. The method of claim 1 , wherein the current does not substantially irritate the subject's skin.

3. The method of claim 2 , wherein the current does not result in a skin erythema score of greater than 2.5, of greater than 2.0, of greater than 1.5, or of greater than 1.0, immediately after patch removal.

4. The method of claim 1 , wherein the subject is a human.

5. The method of claim 1 , wherein the subject is suffering from a prodromal migraine symptom, and wherein the prodromal migraine symptom is treated.

6. The method of claim 1 , wherein the subject is suffering from a migraine aura, and wherein the migraine aura is treated.

7. The method of claim 1 , wherein the photophobia or phonophobia is treated without migraine-associated absorption reduction.

8. The method of claim 1 , wherein the migraine is aborted in the subject.

9. The method of claim 1 , wherein the photophobia or phonophobia is treated without triptan side effects.

10. The method of claim 1 , wherein the photophobia or phonophobia is treated for at least two hours.

11. The method of claim 1 , wherein the migraine is treated for at least two hours.

12. The method of claim 1 , wherein the subject is suffering from a migraine with a pain severity score of 2 or 3.

13. The method of claim 1 , wherein the triptan compound is a sumatriptan or a pharmaceutically acceptable salt thereof.

14. The method of claim 13 , wherein the subject's headache score is reduced from a score of about 3 to about 2, to about 1, or to about 0.

15. The method of claim 13 , wherein the subject's headache score is reduced from a score of about 2 to about 1, or to about 0.

16. The method of claim 13 , wherein iontophoretically administering the triptan compound comprises a current which results in minimal or no erythema.

Assignees

• Nupathe Inc
• Teva Pharmaceuticals Int Gmbh

Inventors

• Sebree Terri B
• Pierce Mark
• O'Neill Carol

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title

• A61P25/06

  Antimigraine agents · CPC title

• A61K31/403

  condensed with carbocyclic rings, e.g. carbazole · CPC title

• A61K9/7023

  Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006) · CPC title